

LAW OFFICES
WILLIAMS & CONNOLLY^{LLP*}

THOMAS S. FLETCHER
(202) 434-5497
tfletcher@wc.com

680 MAINE AVENUE SW
WASHINGTON, DC 20024
(202) 434-5000
WWW.WC.COM

EDWARD BENNETT WILLIAMS (1920-1988)
PAUL R. CONNOLLY (1922-1978)

December 16, 2022

CONFIDENTIAL—SUBJECT TO PROTECTIVE ORDER

Via Email

Neil B. McLaughlin, Esq.
Rakoczy Molino Mazzochi Siwik
6 West Hubbard Street
Chicago, IL 60654
nmclaughlin@rmmslegal.com

Re: ***Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceutical Inc.,
No. 22-cv-61-TSK***

Dear Neil:

As discussed on our call today, I write to memorialize Regeneron's narrowing of the case ahead of the Court's ordered deadline.

As part of Regeneron's continued good-faith effort to narrow the scope of the case, Regeneron will not proceed with asserting U.S. Patents 11,053,280 and 11,299,532 in the first stage of the litigation. Regeneron also will not assert claims 7, 8, 9, 10, and 11 of U.S. Patent 11,104,715. While Regeneron is not required to drop 38 claims and two patents over a month ahead of the Court's Scheduling Order deadline for narrowing, Regeneron does so as part of its continuing effort to streamline the case.

Due to Regeneron's substantial narrowing of the case, Mylan's November 20, 2022 Notice of 30(b)(6) Depositions to Regeneron lists topics that are no longer relevant to the first stage of litigation. As such, Regeneron is amending its designations that it provided on December 12, 2022.

1. Topic No. 1

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. The other designees remain the same.

December 16, 2022

Page 2

2. Topic 4

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. The other designees remain the same.

3. Topic 17

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. The other designees remain the same.

4. Topic 23

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. The other designees remain the same.

5. Topic 59

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, nor claims 7, 8, 9, 10, and 11 in the '715 patent, we are de-designating Andrew Tustian. We are not designating another witness.

6. Topic 60

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

7. Topic 61

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

8. Topic 62

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

9. Topic 63

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

10. Topic 64

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

December 16, 2022

Page 3

11. Topic 65

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, nor claims 7, 8, 9, 10, and 11 in the '715 patent, we are de-designating Andrew Tustian. We are not designating another witness.

12. Topic 66

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

13. Topic 67

Because Regeneron is no longer asserting the '280 and '532 patents as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

14. Topic 68

Because Regeneron is no longer asserting the '280 patent as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

15. Topic 69

Because Regeneron is no longer asserting the '532 patent as part of its Initial Patents, we are de-designating Andrew Tustian. We are not designating another witness.

* * * *

To further reduce the scope of the case, we invite Mylan to identify any topics from Regeneron's 30(b)(6) Notice that it believes no longer to be relevant due Regeneron's narrowing of the case.

Please let us know if you would like to discuss further.

Sincerely,



Thomas S. Fletcher